Follow Us:Follow Us on Twitter Like Us on Facebook Follow Us on Google+ Watch videos on our Youtube channel
IBD Drug Discovery and Development Unit
Cedars-Sinai provides virtually every known gastroenterologic analytical procedure and treatment for digestive diseases and disorders. Cedars-Sinai combines inpatient and outpatient programs and state-of-the-art technology, specialized and internationally renowned physicians, and a body of research.
Our role in IBD Digestive Disease Research is to discover new therapeutics and share cutting edge knowledge about the digestive system and the diseases that impact the lives of millions across the world. We offer a team of research-scientists and clinicians who believe in a "bench to bedside" approach to moving discoveries out of laboratories and closer to reality in clinical trials and the treatment of patients with digestive diseases.
Through our research, we seek to speed up the drug discovery process and help put new therapeutic drugs on the market.
The Cedars-Sinai Inflammatory Bowel Disease Drug Discovery and Development Unit (IBD3) is composed of a unique team of research-scientists and clinicians seeking to discover and share cutting-edge knowledge through collaboration with pharmaceutical companies.
Our unit is committed to predicting the success of current and future IBD therapeutics through personalized medicine.
The IBD Drug Discovery and Development Unit's research-scientists and clinicians not only share research findings and clinical needs with their industry partners, they also support and foster ideas toward seeking the:
- Discovery of potential therapeutic targets
- Validation of targets and biomarker identification through access to clinical samples
- Optimization of successful drug development through patient stratification
- Rescue or repurposing of failed drugs through identification of drug-responsive patient populations
Partnering with our IBD Drug Discovery and Development Unit creates an unprecedented opportunity to accelerate the drug discovery process for treating inflammatory bowel disease, from the laboratory to clinical trials and patient treatments.
In the 2012-13 U.S. News and World Report Best Hospitals issue, Cedars-Sinai was ranked 6th in the nation in Gastroenterology and first in the West.